Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ENCORE1-CNS: Reduced Dose Efavirenz CNS Exposure Sub-study
NCT01451333Phase 3Completed
- Sponsor
- The Kirby Institute
- Start
- Sep 2011
- Primary completion
- Oct 2012
- Modality
- Small Molecules
- Countries
- 3
01
Overview
A Phase 3 trial of efavirenz in human immunodeficiency virus infection (HIV), sponsored by The Kirby Institute. Started Sep 2011; status: completed.
02
Drugs
efavirenz
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT01451333.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01451333.